gastroesophageal junction cancer Archives

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By

Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ASCO GI 2022

21 March, 2022 11:22

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By

Dr Jiafu Ji, Beijing Cancer Hospital, China

Trial

Phase 1/2, AK104-201

Conference

ASCO GI 2022

21 March, 2022 11:19

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By

Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Trial

Phase 2, DESTINY-Gastric01

Conference

ASCO GI 2022

21 March, 2022 11:17

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

21 March, 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

21 March, 2022 11:08

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

19 November, 2021 09:41

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

Presented By

Prof. Zev Wainberg, UCLA, USA

Trial

Phase 2, FIGHT

Conference

ASCO GI 2021

12 March, 2021 11:50

OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward

Presented By

Prof. Josep Tabernero, Vall d'Hebron Institute of Oncology, Spain

Trial

Adjuvant nivolumab: good quality-of-life

Presented By

Prof. Eric Van Cutsem, University of Leuven, Belgium

Trial

Phase 3, CheckMate 577

Conference

ASCO GI 2021

12 March, 2021 11:40

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Conference

ESMO 2020

25 November, 2020 15:08

Medical Conferences

Tag: gastroesophageal junction cancer

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

AK104 plus chemotherapy promising first-line option for gastric cancer

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Updates on pembrolizumab for oesophageal and gastric cancer

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward

Adjuvant nivolumab: good quality-of-life

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?